Policy News
White House Warned of Possible Disruption in Medical Device Supply
AdvaMed President and CEO, Scott Whitaker, recently sent a letter to President Biden outlining concerns about how more stringent ethylene oxide (EtO) requirements could stop medical devices from reaching patients. “With 20 billion medical devices sterilized using EtO each year in the U.S. at about only 100 facilities, the closure of even a small percentage…
Read MoreFDA Seeks Regulatory Oversight Over CBD Products
The Food and Drug Administration (FDA) released a statement indicating the need for a new regulatory pathway to allow for greater oversight and to better manage risks associated with cannabidiol (CBD) products, including products currently marketed as conventional foods and dietary supplements as well as products marketed for animal use. Few details were provided about the proposed…
Read MoreNew Michigan Legislative Session Kicks Off
Michigan’s new legislative session for the 2023-24 term is off and running. Turnover in the Michigan House is 52%, whereas the Senate is home to 16 new members (a 45% turnover). Leadership are now in place for both parties, as are committee assignments, with the Democrats in the majority in both chambers for the first…
Read MoreHouse Passes CHIPS Act
President Biden signed into law the $280 billion CHIPS (Creating Helpful Incentives to Produce Semiconductors) and Science Act, a bill that would subsidize domestic semiconductor manufacturing and invest billions in science and technology innovation, in a bid to strengthen the United States’ competitiveness and self-reliance in what is seen as a keystone industry for economic and…
Read MoreSenate Considers Drug Pricing Controls Legislation
In the waning days before the August recess, Senate Democrats are pushing legislation with anti-science drug price controls, as part of a so-called reconciliation bill. The legislation could undercut its own goals by depriving drugmakers of incentives for developing blockbuster medicines, plus lower-cost biosimilars and generics, several analysts and industry groups have warned. Predictions are that…
Read MoreRecent White House Proposals on Cancer Research Would be Counterproductive
Earlier this year, the Biden Administration aimed to reignite the Cancer Moonshot through its proposed federal budget and an objective to reduce cancer mortality by 50% over the next 25 years. The White House proposes to increase public funding for cancer research and at the same time control the price of cancer treatments. A University…
Read MorePODCAST: Accelerated Approval Study and Implications for Rare Disease Patients
This podcast discusses the results of Vital Transformation’s latest research study outlining the impact of proposed changes to the Accelerated Approval pathway, and what this would mean for patients with rare conditions. The study quantifies the impact of the Accelerated Approval pathway in bringing new therapies for unmet needs to market, and the vital role…
Read MoreMulti-Cancer Early Detection Screening Coverage Act
MichBio is among over 400 groups from all 50 states that have signed the Prevent Cancer Foundation’s letter to Congress encouraging passage of the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 1946 / S. 1873). The legislation has reached an exciting milestone with over half of the U.S. House of Representatives having co-sponsored the bill. As a reminder,…
Read MoreCybersecurity Front and Center for Feds
Congress is considering several pieces of legislation requiring the FDA to regularly update cybersecurity guidance and better coordinate efforts with other agencies to better safeguard of medical and healthcare technologies from digital threats. A bipartisan proposal, the Strengthening Cybersecurity for Medical Devices Act, would require the agency to review and update premarket medical device cybersecurity guidance…
Read MoreSenate Committee Advances PBM Transparency Legislation
The Senate Commerce Committee passed legislation, Pharmacy Benefit Manager Transparency Act of 2022 (S. 4293) , that is designed to address how PBMs control drug prices and can potentially reduce the amount independent pharmacies and consumers pay for medicine. PBMs manage prescription drug benefits for insurance plans and payers. They receive rebates and discounts on…
Read More